TRAW
Traws Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.30
−1.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.7M | 2.8M | 226.0K | 226.0K | 226.0K |
| Cost of Revenue | — | — | 12.0K | — | — |
| Gross Profit | 2.7M | 2.8M | 214.0K | 226.0K | 226.0K |
| Operating Expenses | |||||
| R&D Expense | 17.1M | 12.1M | 130.3M | 11.4M | 11.4M |
| SG&A Expense | 8.1M | 8.5M | 12.3M | 9.1M | 8.4M |
| General & Admin Expense | 8.1M | 8.5M | 12.3M | 9.1M | 8.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | (93.0M) | — | — |
| Total Operating Expenses | 25.2M | 20.7M | 49.6M | 20.5M | 19.9M |
| Cost and Expenses | 25.2M | 20.7M | 49.6M | 20.5M | 19.9M |
| Operating Income (EBIT) | (22.5M) | (17.9M) | (49.3M) | (20.3M) | (19.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | (63.0K) | 27.0M | (117.2M) | 1.4M | 663.0K |
| Non-Operating Income (excl Interest) | — | — | 117.2M | — | — |
| EBT (Pre-Tax Income) | (22.6M) | 9.2M | (166.5M) | (18.9M) | (19.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (14.5M) | 9.2M | (54.7M) | (18.9M) | (19.0M) |
| Earnings from Cont. Ops | (22.6M) | 9.2M | (166.5M) | (18.9M) | (19.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.2M) | 6.9M | (54.7M) | (18.9M) | (19.0M) |
| Per Share | |||||
| Basic EPS | ($0.77) | $0.83 | ($35.21) | ($22.57) | ($22.68) |
| Diluted EPS | ($0.77) | $0.82 | ($35.21) | ($22.57) | ($22.68) |
| Revenue Per Share | $0.26 | $0.34 | $0.15 | $0.27 | $0.27 |
| Shares | |||||
| Basic Shares Outstanding | 10.6M | 8.2M | 1.6M | 839554 | 836329 |
| Diluted Shares Outstanding | 10.6M | 8.4M | 1.6M | 839554 | 836329 |
| Profitability Metrics | |||||
| EBITDA | (22.4M) | (17.8M) | (166.5M) | (20.3M) | (19.6M) |
| D&A | 133.0K | 61.0K | 12.0K | 16.0K | 14.0K |
| EBIT | (22.5M) | (17.9M) | (166.5M) | (20.3M) | (19.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026